PHESGO® is a subcutaneous combination of pertuzumab and trastuzumab for HER2-positive breast cancer, designed to reduce treatment time.
Product not listed ? Send us a DM !
Site is undergoing background updates...Kindly bear with us Dismiss
PHESGO® is a subcutaneous combination of pertuzumab and trastuzumab for HER2-positive breast cancer, designed to reduce treatment time.